Current Report Filing (8-k)
April 27 2017 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 21, 2017
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
001-36457
|
|
90-0031917
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)
(866)
594-5999
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of
Listing.
On April 21, 2017, the NYSE MKT LLC (the NYSE MKT) filed a Form 25 with the Securities and Exchange
Commission (the SEC), notifying the SEC of the NYSE MKTs intention to remove the shares of common stock (Common Stock) of Provectus Biopharmaceuticals, Inc. (the Company) and the Companys class of
warrants with an exercise price of $0.85 per share expiring June 19, 2020 (the Listed Warrants) from listing and registration on the NYSE MKT effective May 1, 2017, pursuant to the provisions of Rule
12d2-2(b)
of the Securities Exchange Act of 1934, as amended. The NYSE MKTs filing of the Form 25 followed the NYSE MKT Committee for Reviews determination on April 5, 2017 to affirm the
January 31, 2017 decision of the NYSE MKT Listing Qualifications Panel to initiate delisting proceedings due to (i) the abnormally low trading price of the shares of the Common Stock and (ii) the Companys
noncompliance with Section 1003(a)(iii) of the NYSE MKT Company Guide (requiring stockholders equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal
years).
The Common Stock and Listed Warrants will continue to trade on the OTCQB following the delisting from the NYSE MKT under the
trading symbols PVCT and PVCTWS, respectively. The Company can provide no assurance that the Common Stock and Listed Warrants will continue to trade on the OTCQB in the future.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: April 27, 2017
|
|
|
PROVECTUS BIOPHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Timothy C. Scott
|
|
|
Timothy C. Scott
|
|
|
President
|
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024